Selected Publications
Below are a selection of publications that are associated with Etubics next generation adenovirus vector.
Cancer Immunol Immunotherapy July 2010
Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA
Expert Opinion on Biological Therapy, December 2009
Overcoming pre-existing Adenovirus immunity by genetic engineering of adenovirus-based vaccine vectors
Vaccine, October 2009
Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity
Cancer Gene Therapy, February 2009
Optimization of vaccine responses with an E1, E2b and E3- deleted Ad5 vector circumvents pre-existing anti-vector immunity.
Immunology Letters November 2008
A Preliminary and Comparative Evaluation of a Novel Ad5 [E1-, Eb2-] Recombinant Based Vaccine Used to Induce Cell Mediated Immune Responses
Gene Therapy, October 1999
Next generation adenoviral vectors: new and improved.
Journal of Virology February 1998
Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted
Gene Therapy, March 1997
Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy
Proceedings of the National Academy of Sciences of the United States of America April 1996
Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors.